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Abstract
Significant information indicates that future investigations on Toxoplasma vaccine devel-
opment have to include adjuvants for enhancing protective immunity against Toxoplasma 
gondii. Especially, safe and effective adjuvants capable of fulfilling Th1‐dependent cell‐
mediated immunity appear to be more likely to be allowed to use for anti Toxoplasma 
vaccine development. Recently, biodegradable and biocompatible polymers, such as poly 
(lactide‐co‐glycolide) (PLG) polymers, have been utilized as safe and efficacious adju-
vants to encapsulate antigens for producing long‐term release microparticle‐based vac-
cines. PLG microencapsulation allows the sustained release of antigens and facilitates 
antigen uptake via antigen‐presenting cells (APCs) to favorably generate Th1 cell‐medi-
ated immunity, which is required for the prevention of T. gondii infection. In our recent 
work, recombinant surface antigens (rSAGs), including rSAG1, rSAG2, and rSAG1/2, have 
been, respectively, encapsulated with the PLG polymer for production of PLG‐encapsu-
lated rSAG1 (PLG‐rSAG1), PLG‐encapsulated rSAG2 (PLG‐rSAG2), or PLG‐encapsulated 
rSAG1/2 (PLG‐rSAG1/2) microparticles. This chapter describes adjuvant effect of PLG 
microparticles, controlled release of PLG microparticles, PLG microparticles‐immune 
system interaction, Toxoplasma SAG‐loaded PLG microparticles, protective immunity 
by Toxoplasma SAG‐loaded PLG microparticles, and future prospects. PLG microparticle 
 vaccines would be advantageous for their application in the development of long‐lasting 
vaccines against T. gondii for future use in humans and animals.
Keywords: adjuvants, poly(lactide‐co‐glycolide) (PLG), antigen‐presenting cells (APCs), 
PLG‐rSAG1 microparticles, PLG‐rSAG2 microparticles, PLG‐rSAG1/2 microparticles
1. Introduction
Toxoplasma gondii is an intracellular protozoan parasite that uses felines as final hosts and 
various endothermic animals, including humans, as intermediate hosts [1]. Toxoplasmosis is 
of major clinical and veterinary importance. The infection in domestic animals such as sheep 
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
or pigs usually generates adverse economic impact due to the induction of severe abortion 
and neonatal loss [2]. In addition, toxoplasmosis in pregnant women may result in severe 
congenital fetal disorders, including hydrocephaly, blindness, and mental retardation [3]. 
Toxoplasmosis in immunocompromised individuals such as AIDS patients often develops 
lethal toxoplasmic encephalitis as an important opportunistic infection [4]. Although pro-
phylactic anti‐Toxoplasma vaccines have been studied for a long time, only one commercial 
attenuated vaccine (Toxovax) has been licensed for use in sheep [5]. Most inactivated and 
recombinant vaccines developed in the past have produced only little to moderate protective 
efficacy against infections with a lethal challenge dose of the virulent strain of T. gondii [6].
Numerous earlier studies have demonstrated that cell‐mediated immunity is considered as the 
‘appropriate’ immune response in the prevention of T. gondii infection [7]. Therefore, potent 
adjuvants that can improve cell‐mediated immunity have to include in Toxoplasma vaccine 
development in the future. In addition, gamma interferon (IFN‐γ), one of Th1‐type cytokines, 
mainly produced by CD4+ Th1 cells is able to subsequently stimulate CD8+ Tc cells to convert 
into cytotoxic effector cells for preventing acute and chronic T. gondii infection [6–8]. Thus, 
effective protection against T. gondii infection is critically dependent on the IFN‐γ‐associated 
Th1 cell‐mediated immunity. Therefore, effective vaccines formulated with potent adjuvants 
that are promised to induce an IFN‐γ‐associated Th1 cell‐mediated immune response seem 
more likely to be approved for use.
Most modern vaccines based on subunits of pathogens, such as purified proteins, are likely 
to be less immunogenic than traditional vaccine antigens and are often unable to initiate a 
strong immune response [9]. These subunit vaccines require effective adjuvants to aid them 
to elicit strong protective immune responses [10, 11]. Therefore, one of the current important 
issues in vaccinology is the urgent need for the development of new or improved adjuvants 
to enhance the immunogenicity or effectiveness of vaccines [9, 10, 12]. Different adjuvants 
capable of improving immunity and protection have been described in numerous studies 
[9, 10, 12]. However, the safety concern of an adjuvant is still a crucial issue to limit adjuvant 
development [13].
Adjuvants are special substances used in combination with an antigen to generate a more 
robust immune response than the antigen alone [11, 14, 15]. This broad definition encom-
passes a very wide range of materials for adjuvant development. Actually, adjuvants can be 
broadly separated into two classes, vaccine delivery systems and immunostimulatory agents, 
based on their main mechanisms of action [11]. Vaccine delivery systems are generally par-
ticulate, such as emulsions [16], micro/nano particles [17], iscoms, and liposomes [18], and 
their main function is to deliver antigens into antigen‐presenting cells (APCs) [11]. In con-
trast, immunostimulatory agents are predominantly derived from pathogens and often repre-
sent pathogen‐associated molecular patterns (PAMP), such as lipopolysaccharides (LPS) [19], 
monophosphoryl Lipid A (MPL‐A) [20], and CpG oligodeoxynucleotides (CpG‐ODN) [21], 
which activate cells of the innate immune system to induce the following acquired immune 
response [11].
This chapter will focus predominantly on microparticle adjuvant, especially poly(lactide‐co‐gly-
colide) (PLG) polymer, to be used in tachyzoite surface antigen (SAG)‐based subunit  vaccines 
against T. gondii, the etiological agent of toxoplasmosis. In our recent work, recombinant SAGs 
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(rSAGs), including rSAG1, rSAG2, and rSAG1/2, have been, respectively, encapsulated with 
the PLG polymer for production of PLG‐encapsulated rSAG1 (PLG‐rSAG1) [22], PLG‐encap-
sulated rSAG2 (PLG‐rSAG2) [23], or PLG‐encapsulated rSAG1/2 (PLG‐rSAG1/2) microparticles 
[24]. This chapter describes adjuvant effect of PLG microparticles, controlled release of PLG 
microparticles, PLG microparticles‐immune system interaction, Toxoplasma SAG‐loaded PLG 
microparticles, protective immunity by Toxoplasma SAG‐loaded PLG microparticles, and future 
prospects. The capability of these PLG microparticle vaccines to control the stable release of 
antigenic rSAG1 and effectively induce and extend protective immunity would be advanta-
geous for their application in the development of long‐lasting vaccines against T. gondii for 
future use in humans and animals.
2. Adjuvants effects of PLG microparticles
Microparticles, one of the vaccine delivery systems, derived from different biodegradable 
and biocompatible polymers, including poly(lactide‐co‐glycolide), alginate, starch, and 
other carbohydrate polymers, can be designed as safe carriers for proteins or drugs to 
perform the main function of delivery systems [25]. Particularly, PLG polymers approved 
by the US Food and Drug Administration (FDA) have been extensively used as sutures 
[26] and drug carriers [27] for many years. Different forms of PLG polymers can be gener-
ated according to the ratio of lactide to glycolide used for the polymerization [28]. In the 
recent 10 years, PLG polymers have further become safe and potent adjuvants or delivery 
systems to encapsulate vaccine antigens for the development of controlled release mic-
roparticle vaccines [29]. The PLG microparticles are biodegradable through hydrolysis to 
break down into the biocompatible metabolites, lactic and glycolic acids, which produce 
little inflammatory activity and are excreted from the body via natural metabolic path-
ways [28]. PLG polymers provide a number of practical advantages in acting as vaccine 
adjuvants or delivery systems following PLG encapsulation. The PLG microencapsulation 
protects antigens from unfavorable degradation [30], allows the sustained and extended 
release of antigens for a long period [31], and enhances antigen uptake by APCs, such as 
macrophages and dendritic cells, in specific lymphoid regions [32]. These adjuvant effects 
strengthen antigen immunogenicity to favorably generate strong specific immunity, espe-
cially cell‐mediated immunity [29], which is urgently required for eliminating intracellular 
pathogens, such as T. gondii.
3. Microparticles‐immune system interaction
Earlier significant studies have shown that potent cell‐mediated immunity induced by PLG 
microparticles following vaccination is likely to be due to the uptake of PLG microparticles 
into APCs and the effective delivery of microparticle‐containing APCs to specific lymphoid 
compartments [25, 32, 33]. The size of PLG microparticles used for animal vaccination is a cru-
cial parameter in facilitating the uptake of APCs [32]. Particles smaller than 10 μm in diameter 
are appropriate for direct uptake by APCs, such as macrophages and dendritic cells [25, 32]. 
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The proper size range thus can stimulate APCs to facilitate the microparticle uptake. Following 
the uptake of microparticles, the APCs containing microparticles then migrate to other lym-
phoid compartments [25], such as the spleen and mesenteric lymph nodes, where they effec-
tively present antigenic epitopes to T lymphocytes, especially Th1 and Tc, thereby inducing 
strong specific cell‐mediated immunity [32, 33]. In other words, facilitation of uptake and 
delivery of PLG microparticles by APCs can lead to more effective antigen processing and pre-
sentation to T lymphocytes capable of inducting cell‐mediated immune responses [25, 32–34]. 
Significant earlier studies have further demonstrated that the APCs containing microparticles 
can travel to specialized mucosal lymphoid compartments, including mucosal‐associated lym-
phoid tissues (MALTs), the inductive sites for stimulating potent immunity following intrana-
sal or oral vaccination [35, 36]. Thus, PLG‐encapsulated antigens can be designed as effective 
mucosal vaccines that have potential to stimulate mucosal systems, such as intestinal and 
 vaginal tracks via intranasal or oral administration [36].
4. Controlled release of PLG microparticles
The capability of PLG microparticles to regulate the extended release rate of PLG‐encapsu-
lated antigens can lead to long‐term immunity in microparticle‐vaccinated animals [29, 37]. 
Various studies have demonstrated that PLG microparticles may perform pulsed and/or slow 
release of encapsulated antigens to promote effective immune responses [38]. The sustained 
and extended antigen release appears to substantially enhance and prolong antigen‐specific 
immunity for achieving long‐term protection [29, 31]. The antigen release from PLG mic-
roparticles is controlled by the degradation rate of PLG copolymer, which is largely due to 
the ratio of lactide to glycolide of PLG polymer, the molecular weight, and hydrophilicity of 
PLG polymer as well as the characteristics of PLG microparticles such as the morphology, 
size, and encapsulation efficiency [38]. The sustained antigen release of antigen‐loaded PLG 
microparticles have been applied in the development of various potent microparticle vac-
cines [29, 31]. In addition, antigen‐loaded PLG microparticles capable of sustaining release of 
an antigen also show potential for being designed as a single‐dose vaccine without the need 
for booster doses [37, 39]. However, as some sophisticated events, including enhancement of 
protein load in PLG microparticles as well as optimization and stabilization of protein release 
are involved in the design of a single‐dose vaccine [40], the feasibility needs to be assessed in 
future studies.
5. Encapsulation methods
The microparticles based on biodegradable PLG polymers can be prepared by number of 
methods, such as spray drying, double emulsion, and phase separation‐coacervation [30]. 
However, the most widely used technique for preparation of protein‐loaded microparticles is 
the double emulsion method [30].
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The protein is encapsulated in 50:50 poly(lactide‐co‐glycolide) microparticles using the 
double emulsion method as described previously [41, 42], with minor modifications [22–24]. 
In the process, PLG polymer is first dissolved in an organic solvent. The organic solvent 
dichloromethane is mainly used to dissolve PLG polymer. Protein in aqueous solvent is then 
emulsified with nonmiscible organic solution of PLG polymer by high speed homogenization 
or sonication to produce a water/oil emulsion. The resulting emulsion is further transferred 
to a solution of polyvinyl alcohol, which is used as a stabilizer. Again homogenization or 
intensive stirring is necessary to generate a double emulsion of water/oil/water. The water/oil/
water emulsion is then stirred for 18 h at room temperature (RT) and pressurized to promote 
solvent evaporation and microparticle formation in a laboratory fume hood. Solvent extrac-
tion can also be undertaken yielding microparticles containing protein. The microparticles are 
collected by centrifugation and washed with distilled water to remove nonentrapped protein.
Based on previous studies, proteins used for PLG encapsulation can be scaled down by using 
the water/oil/water double emulsion method [30]. In addition, this method also results in high 
microparticle yields and encapsulation efficiencies [30]. However, there is still a potential con-
cern of antigen denaturation due to organic solvent exposure during the encapsulation process 
[41, 42], although numerous proteins have been successfully entrapped in PLG microparticles 
without loss of structural integrity, immunogenicity, or bioactivity [25, 30]. Especially, antige-
nicity retention following the process of double emulsion method is a critical event to subse-
quently initiate effective immunity by vaccinating antigen‐loaded microparticles [30].
6. Preparation of Toxoplasma SAG‐loaded microparticles
Development efforts of subunit vaccines against T. gondii in our laboratory have been focused 
mainly on the major immunodominant SAGs of tachyzoites [22–24, 43, 44], the rapidly mul-
tiplying stage during the acute phase infection. Furthermore, SAG1 and SAG2 proteins have 
been identified as two major tachyzoite SAGs in the previous study [45]. These two pro-
teins are involved in the process of host cell invasion [46] and can induce anti Toxoplasma 
immune responses [6]. Therefore, both SAG1 and SAG2 can be considered as potential can-
didate antigens for Toxoplasma vaccine development. SAG1 gene, SAG2 gene, and a hybrid 
gene consisting of SAG1 and SAG2 sequences had been, respectively, cloned in our previous 
work to produce recombinant SAG1 (rSAG1) protein [22, 43], recombinant SAG2 (rSAG2) 
protein [23, 43], and a recombinant chimeric protein, rSAG1/2 [24, 43]. Further animal stud-
ies in mice demonstrated that rSAG1, rSAG2, or rSAG1/2 emulsified with an oil adjuvant, 
Vet L‐10, induced partial protection against a lethal subcutaneous challenge of T. gondii 
tachyzoites [43]. If alternative effective adjuvants, such as the PLG polymer are used to make 
these recombinant proteins more immunogenic, more protective immunity against T. gondii 
may be achieved in animals.
In our recent work, rSAG1, rSAG2, or rSAG1/2 was then, respectively, encapsulated with 
the PLG polymer by using the double emulsion method for production of PLG‐encapsulated 
rSAG1 (PLG‐rSAG1) [22], PLG‐encapsulated rSAG2 (PLG‐rSAG2) [23], or PLG‐encapsulated 
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Microparticle Release protein Release period Release profile Reference
PLG‐rSAG1 87.8% rSAG1 35 days Three phases [22]
PLG‐rSAG2 88.3% rSAG2 33 days Three phases [23]
PLG‐rSAG1/2 88.5% rSAG1/2 56 days Three phases [24]
Table 2. Release of rSAG from PLG microparticles.
rSAG1/2 (PLG‐rSAG1/2) microparticles [24]. Some microparticle characteristics, such as size 
(diameter), microparticle morphology, protein entrapment, and in vitro release were ana-
lyzed after PLG encapsulation (Tables 1 and 2). The morphological studies based on scanning 
electron microscopy showed that these microparticles are uniform population of spherical 
particles with a smooth surface. In addition, particle sizes of all three PLG microparticles 
in diameter were smaller than 10 μm (Table 1). Thus, the three PLG microparticles have an 
appropriate feature for direct uptake by APCs, such as macrophages and dendritic cells.
More importantly, the release of rSAG1, rSAG2, or rSAG1/2 from PLG microparticles was 
also analyzed (Table 2). We found that the in vitro cumulative release of rSAG1, rSAG2, and 
rSAG1/2 from PLG microparticles suspended in phosphate buffered saline (PBS) could be, 
respectively, sustained for 35, 33, and 56 days with three distinct phases consisting of an 
initial burst release, a very slow release, and a final rapid release (Table 2). Actually, based 
on previous critical investigations, such three‐phase fluctuation in antigen release from PLG 
microparticles is due to the initial rapid diffusion of coated antigen on the PLG microparticle 
surface, the very slow and gradual diffusion of encapsulated antigen, and the final rapid 
diffusion of antigen because of the PLG microparticle degradation [47–49]. Furthermore, in 
the triphasic antigen release profile, both initial and final rapid release of entrapped antigen, 
respectively, look like priming and boosting doses usually employed in a conventional immu-
nization procedure [49]. Thus, vaccination with a single dose of PLG‐rSAG microparticles 
that are able to fulfill the triphasic rSAG release may be thought of as treating with two doses 
of rSAG protein. However, further improvements such as enhancement of protein load in 
PLG microparticles, as well as, optimization and stabilization of protein release are needed 
to evaluate the feasibility [40]. On the other hand, Western blotting assay with use of mouse 
monoclonal antibodies specific to tachyzoite SAGs demonstrated that released rSAG proteins 
from PLG microparticles still retained the original SAG antigenicity during the release from 
PLG microparticles [22–24]. These data indicate that both the encapsulation procedure and 
release from microparticles in our previous work are not detrimental to the antigenicity of 
Microparticle Mean particle size (μm) Entrapment efficiency (%) Reference
PLG‐rSAG1 4.25–6.58 69–81 [22]
PLG‐rSAG2 2.14–3.63 74–80 [23]
PLG‐rSAG1/2 1.27–1.65 72–83 [24]
Table 1. Particle size and entrapment efficiency of PLG‐rSAG microparticles.
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rSAG. Thus, rSAG proteins have been successfully encapsulated with PLG polymers by the 
double emulsion method and the resulting PLG‐rSAG microparticles not only properly pre-
served the SAG’s antigenicity, but also sustained the controlled, stable release of the antigenic 
rSAG proteins from PLG microparticles. Based on these data, therefore, released rSAG pro-
teins from PLG microparticles have the potential to induce anti SAG immune responses.
7. Protective immunity by Toxoplasma SAG‐loaded microparticles
Although different adjuvants capable of improving immune responses and protection against 
T. gondii have been studied [6, 50], the biodegradable and biocompatible PLG polymers are 
so far seldom used as potent adjuvants for Toxoplasma vaccine development. Stanley and his 
coauthors first employed the double emulsion method to produce PLG‐encapsulated mic-
roparticle vaccine against T. gondii [51]. In the same study, the PLG microparticle vaccine 
containing a tachyzoite extract plus a mucosal adjuvant, cholera toxin, failed to provide pro-
tection in sheep [51]. The unexpected protection in sheep indicates that more effort is there-
fore needed to improve not only the stability of encapsulated Toxoplasma antigens but also the 
immune responses and protection they induce in animals.
On the other hand, the adjuvant effects of the PLG encapsulation had been exercised to, 
respectively, prepare PLG‐rSAG1, PLG‐rSAG2, and PLG‐rSAG1/2 microparticles in our three 
previous studies [22–24]. The ability of these PLG‐rSAG microparticles to trigger protec-
tive immunity against T. gondii was subsequently evaluated in BALB/c mice by vaccination 
through the intraperitoneal route. Results showed that both PLG‐rSAG1 and PLG‐rSAG1/2 
microparticles effectively induced not only significant long‐lasting (10 weeks) specific humoral 
and cell‐mediated immune responses, accompanied by secretion of a large amount of IFN‐γ, 
but also high protection (80% for PLG‐rSAG1 microparticles and 83% for PLG‐rSAG1/2 mic-
roparticles) against T. gondii tachyzoite infection [22, 24]. However, PLG‐rSAG2 micropar-
ticles could induce sustained (10 weeks) lymphocyte proliferation and IFN‐γ production [23]. 
Furthermore, after a lethal subcutaneous challenge of 1 × 104 T. gondii tachyzoites (RH strain), 
PLG‐rSAG2 microparticles also improved anti Toxoplasma protection (87%) [23], which is 
higher, though not statistically significant, than either 80% of PLG‐rSAG1 microparticles [22] 
or 83% of PLG‐rSAG1/2 microparticles [24].
As T. gondii is an obligate intracellular parasite, protective immunity to T. gondii is largely 
mediated by Th1 cell‐mediated immunity [6, 7]. Previous studies have shown that induction 
of both lymphocyte proliferation and IFN‐γ production (one of Th1‐type cytokines) positively 
correlates with protective Th1 cell‐mediated immunity against T. gondii [43, 44, 51]. In addi-
tion, IFN‐γ has been demonstrated to be a critical mediator that has to be secreted for as long 
as possible in order to maintain anti Toxoplasma immunity [52, 53]. We found that sustained 
lymphocyte proliferation and significant IFN‐γ production readily detected in mice immu-
nized with PLG‐rSAG microparticles in our previous studies [22–24]. These findings indicate 
that immunization with PLG‐rSAG microparticles really elicits the IFN‐γ‐associated Th1 cell‐
mediated immunity, which is the expected response that we aimed to induce in mice.
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Based on previous studies, PLG microparticles appear to favorably facilitate a size‐depen-
dent interaction with APCs, such as macrophages and dendritic cells [32–34]. The particles, 
like PLG‐rSAG microparticles prepared in our previous studies (Table 1), smaller than 10 
μm in diameter are directly taken by APCs [32]. Based on our previous results, the proper 
size range thus could stimulate peritoneal macrophages to facilitate the uptake of these PLG‐
rSAG microparticles administered in the mouse peritoneal cavity [22–24]. Therefore, the mic-
roparticle‐containing macrophages in the peritoneal cavity then traveled to other lymphoid 
compartments, including the spleen, and effectively presented SAG epitopes to Th1 and Tc; 
thereby, inducing strong SAG‐specific Th1 cell‐mediated immunity to protect mice from the 
tachyzoite challenge. Our previous studies [22–24] and those recorded by others [32–34] have 
shown that facilitation of uptake and delivery of PLG‐rSAG microparticles by macrophages 
can lead to more effective antigen processing and presentation to T lymphocytes capable of 
inducting cell‐mediated immunity. Thus, the high survival rates in mice have demonstrated 
that PLG‐rSAG microparticles effectively elicit protective Th1 cell‐mediated immunity to 
remove tachyzoite‐infected cells for limiting parasite dissemination during the experimental 
tachyzoite challenge [7].
In addition to Th1‐dependent cell‐mediated immunity, in our previous studies, high titers of 
anti Toxoplasma IgG in mouse sera elicited by PLG‐rSAG microparticles have indicated that 
systemic humoral immunity mediated by Th2 may participate in the prevention of T. gondii 
infection [54, 55]. However, further measurements by the dye test are still needed to assay 
these antibodies to elucidate their functional lytic activities. Therefore, peritoneal vaccina-
tion of mice with PLG‐rSAG microparticles may generate mixed Th1/Th2 immunity against 
T. gondii.
8. Conclusions and future prospects
PLG polymers are the primary candidates for the development of microparticle vaccines [25]. 
The rSAG proteins (rSAG1, rSAG2, and rSAG1/2) prepared in our laboratory have been suc-
cessfully encapsulated with PLG polymers to generate PLG‐rSAG microparticles capable of 
sustaining long‐term stable release of antigenic rSAG proteins. Moreover, following perito-
neal immunization in mice, PLG‐rSAG microparticles induce not only long‐term (10 weeks) 
SAG‐specific humoral and cell‐mediated immune responses, but also high protection against 
a lethal challenge of T. gondii tachyzoites [22–24]. Our studies provide a valuable basis for 
developing long‐lasting vaccines against T. gondii for future use in humans and animals. 
Our experimental data indicate that the encapsulation procedure we used for production of 
PLG‐rSAG microparticles is feasible at the laboratory level. However, this procedure have 
never been used to try mass production of PLG‐rSAG microparticles. More effort is therefore 
needed to evaluate the optimized encapsulation conditions used to fulfill the need for mass 
production [40].
The PLG‐rSAG microparticles we prepared previously could allow the sustained and extended 
release of rSAG proteins over a long period. Such long‐term release of rSAG  proteins could 
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repeatedly stimulate the immune effector cells to maintain enhanced immunity following 
immunization with PLG‐rSAG microparticles [29, 37]. However, the triphasic rSAG release 
detected in the cumulative release assay we carried out in the previous studies was done in 
vitro in PBS and; therefore, may not completely reflect in vivo release in mice [22–24]. Further 
studies are therefore needed to confirm the critical effect of triphasic rSAG release on in vivo 
anti Toxoplasma immune responses.
One adjuvant effect acted by PLG microparticle vaccines is to facilitate antigen uptake via APCs 
[25, 32, 33]. Different APCs populated in various administrating routes are able to  perform the 
uptake of antigen‐loaded PLG microparticles and then process and present the epitopes of 
PLG‐encapsulated antigen on the major histocompatibility (MHC) molecules [32]. Therefore, 
different routes of delivery of antigen‐loaded PLG microparticles give rise to different vaccine 
efficacy in animals [32]. The mouse protective immunity induced by intraperitoneally admin-
istered PLG‐rSAG microparticles protected mice from a lethal subcutaneous challenge of T. 
gondii tachyzoites. However, such intraperitoneal administration of the microparticle vaccine 
appears to be inappropriate for use in large animals such as sheep or swine. In order to cor-
roborate the conclusions drawn from the mouse model, more studies are needed to evaluate 
the proper route for administration of PLG‐rSAG microparticles in target animals. In addition, 
due to the natural infection initiated by ingesting oocysts released in cat feces or consuming 
meat from infected animals containing the long‐lived tissue cysts, future experiments will also 
be necessary to assess whether mucosal administration (oral or nasal route) of PLG‐rSAG mic-
roparticles protects these animals from an oral challenge of oocysts or tissue cysts of T. gondii.
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